Berthony Deslouches

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9478197/publications.pdf Version: 2024-02-01

		394421	454955
32	1,639	19	30
papers	citations	h-index	g-index
32	32	32	2163
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Rational Framework for the Design of Trp- and Arg-Rich Peptide Antibiotics Against Multidrug-Resistant Bacteria. Frontiers in Microbiology, 2022, 13, .	3.5	3
2	Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice. Current Reviews in Clinical and Experimental Pharmacology, 2021, 16, 263-272.	0.8	1
3	Significance of Secondary Structure Determination When Evaluating Rationally Designed Antimicrobial Peptides. Biophysical Journal, 2020, 118, 394a.	0.5	1
4	Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Science Advances, 2020, 6, eaay6817.	10.3	75
5	Direct antimicrobial activity of cationic amphipathic peptide WLBU2 against <i>Staphylococcus aureus</i> biofilms is enhanced in physiologic buffered saline. Journal of Orthopaedic Research, 2020, 38, 2657-2663.	2.3	12
6	Engineered Cationic Antimicrobial Peptides (eCAPs) to Combat Multidrug-Resistant Bacteria. Pharmaceutics, 2020, 12, 501.	4.5	38
7	Synergistic Biophysical Techniques Reveal Structural Mechanisms of Engineered Cationic Antimicrobial Peptides in Lipid Model Membranes. Chemistry - A European Journal, 2020, 26, 6247-6256.	3.3	9
8	Elastic behavior of model membranes with antimicrobial peptides depends on lipid specificity and <scp> d</scp> -enantiomers. Soft Matter, 2019, 15, 1860-1868.	2.7	21
9	Elastic Behavior of Model Membranes with Antimicrobial Peptides Depends on Lipid Specificity and D-Enantiomers. Biophysical Journal, 2019, 116, 84a.	0.5	0
10	Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection. MBio, 2019, 10, .	4.1	21
11	Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia. Clinical Microbiology and Infection, 2018, 24, 547.e1-547.e8.	6.0	35
12	Enhanced biofilm prevention activity of a SPLUNC1-derived antimicrobial peptide against Staphylococcus aureus. PLoS ONE, 2018, 13, e0203621.	2.5	8
13	Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. International Journal of Antimicrobial Agents, 2018, 52, 667-672.	2.5	81
14	Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. Scientific Reports, 2017, 7, 18098.	3.3	37
15	Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget, 2017, 8, 46635-46651.	1.8	273
16	Engineered Cationic Antimicrobial Peptides Containing Cholesterol Interacting Motifs to Target Viral Envelopes. Journal of Antivirals & Antiretrovirals, 2017, 09, .	0.1	1
17	Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections. Clinics in Surgery, 2017, 2, .	0.8	10
18	Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine. Journal of Medical Microbiology, 2016, 65, 554-565.	1.8	35

Berthony Deslouches

#	Article	IF	CITATIONS
19	Engineered cationic antimicrobial peptide (eCAP) prevents <i>Pseudomonas aeruginosa</i> biofilm growth on airway epithelial cells. Journal of Antimicrobial Chemotherapy, 2016, 71, 2200-2207.	3.0	50
20	Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium Coinfection. MSphere, 2016, 1, .	2.9	27
21	Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei. Journal of Medical Microbiology, 2016, 65, 188-194.	1.8	22
22	Memory T Cells Specific for Murine Cytomegalovirus Re-Emerge after Multiple Challenges and Recapitulate Immunity in Various Adoptive Transfer Scenarios. Journal of Immunology, 2015, 194, 1726-1736.	0.8	33
23	Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens. Antimicrobial Agents and Chemotherapy, 2015, 59, 1329-1333.	3.2	108
24	Antimicrobial peptides: new drugs for bad bugs?. Expert Opinion on Biological Therapy, 2014, 14, 11-14.	3.1	106
25	Rational Design of Engineered Cationic Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan, and Their Activity against Multidrug-Resistant Pathogens. Antimicrobial Agents and Chemotherapy, 2013, 57, 2511-2521.	3.2	147
26	The use of pre-operative imaging and intraoperative parathyroid hormone level to guide surgical management of tertiary hyperparathyroidism from X-linked hypophosphatemic rickets: a case report. Cases Journal, 2009, 2, 7572.	0.4	6
27	De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. Journal of Antimicrobial Chemotherapy, 2007, 60, 669-672.	3.0	56
28	Antimicrobial Peptides in Mucosal Secretions: The Importance of Local Secretions in Mitigating Infection. Journal of Nutrition, 2005, 135, 1289-1293.	2.9	35
29	Activity of the De Novo Engineered Antimicrobial Peptide WLBU2 against Pseudomonas aeruginosa in Human Serum and Whole Blood: Implications for Systemic Applications. Antimicrobial Agents and Chemotherapy, 2005, 49, 3208-3216.	3.2	138
30	De Novo Generation of Cationic Antimicrobial Peptides: Influence of Length and Tryptophan Substitution on Antimicrobial Activity. Antimicrobial Agents and Chemotherapy, 2005, 49, 316-322.	3.2	227
31	Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides, 2003, 24, 1099-1107.	2.4	23
32	Antimicrobial Peptide Mechanisms Revealed with Scattering-Guided Molecular Dynamics Simulation. SSRN Electronic Journal, 0, , .	0.4	0